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Abstract
Background: Estrogen activity plays a critical role in bone homeostasis. The serum levels of sex
hormone binding globulin (SHBG) influence free estrogen levels and activity on target tissues. The
objective of this study was to analyze the influence of common polymorphisms of the SHBG gene
on serum SHBG, bone mineral density (BMD), and osteoporotic fractures.
Methods: Four biallelic polymorphisms of the SHBG gene were studied by means of Taqman assays
in 753 postmenopausal women. BMD was measured by DXA and serum SHBG was measured by
ELISA.
Results: Age, body weight, and two polymorphisms of the SHBG gene (rs6257 and rs1799941 [A/
G]) were significantly associated with serum SHBG in unadjusted and age- and weight-adjusted
models. Alleles at the rs1799941 locus showed the strongest association with serum SHBG (p =
0.0004). The difference in SHBG levels between women with AA and GG genotypes at the
rs1799941 locus was 39%. There were no significant differences in BMD across SHBG genotypes.
The genotypes showed similar frequency distributions in control women and women with
vertebral or hip fractures.
Conclusion:  Some common genetic variants of the SHBG  gene, and particularly an A/G
polymorphism situated in the 5' region, influence serum SHBG levels. However, a significant
association with BMD or osteoporotic fractures has not been demonstrated.
Background
Osteoporosis is a complex disease characterized by
reduced bone mineral density (BMD) and a propensity for
fractures that results from the interaction of genetic and
environmental factors. It has been estimated that the her-
itability of BMD is about 50–80% [1,2]. Estrogens play a
critical role in bone homeostasis, and are essential for the
acquisition and maintenance of bone mass. Estrogen defi-
ciency accounts for the marked decrease in BMD when
gonadal function ceases at the menopause, leading to the
high incidence of osteoporotic fractures in postmenopau-
sal women. However, it must be stressed that estrogens
may still play a role after the menopause. In fact, the aro-
matization of androgenic precursors in the adipose tissue
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and other extragonadal tissues continues during life and
an association between serum estradiol and certain poly-
morphisms of the aromatase gene has been reported [3].
Similar to other lipophilic hormones, estradiol circulates
in the blood bound to proteins, specifically to sex hor-
mone binding globulin (SHBG). The free fraction of the
hormone is the fraction usually considered to be the bio-
logically important form. As a consequence, the levels of
SHBG may influence estradiol bioavailability and cellular
effects. Thus, it is important to understand the factors that
modulate SHBG levels. Some of the factors are well-
known, including pregnancy, exogenous sex steroids, and
body weight [4]. In recent years, some studies have sug-
gested that certain genetic variants of the SHBG  gene
could also influence SHBG levels and estrogen activity on
both normal and neoplastic target tissues. However, the
available data are limited and the reported results are con-
troversial [5-13]. Therefore, the objective of this study was
to analyze the influence of several polymorphisms of the
SHBG  gene on SHBG serum levels, BMD, and oste-
oporotic fractures
Methods
Individuals
We studied a group of 753 postmenopausal women over
60 years of age. They were volunteers recruited by voice
and written announcements or sent to our outpatient
clinic to be studied for possible osteoporosis (n = 463;
age, 70 ± 6 yr), and women admitted to the hospital with
hip fractures due to low-energy trauma (n = 290; age, 78
± 6 yr). All participants were living in Cantabria, a region
in Northern Spain with a population of about 530,000.
They were interviewed by one of the investigators in order
to check the absence of exclusion criteria. Subjects taking
bisphosphonates, corticosteroids, antiepileptics, estro-
gens, or other drugs known to modify bone mass, or with
non-Spanish ancestry, were excluded. The study was
approved by the Institutional Committee on Ethics in
Clinical Research.
Techniques
BMD was determined in control women and women with
spine osteoporosis by anterior-posterior DXA scans at the
lumbar spine (L2–L4) and the total hip region using an
Hologic QDR 4500 densitometer (Hologic, Waltham,
MA, USA). Serum SHBG was measured by ELISA (IBL,
Hamburg, Germany) with a sensitivity of 0.2 nmol/l and
a coefficient of variation of 9%.
Genetic analysis
We used PupaSuite (available at http://pupasuite.bio
info.cipf.es) and FastSNP/VisualSNP (available at http://
genepipe.ngc.sinica.edu.tw/visualsnp/input.do) to iden-
tify potentially functional single nucleotide polymor-
phisms in the SHBG gene. Those web-based tools utilize
several algorithms to identify sequences likely to influ-
ence gene transcription or the function of the gene prod-
uct based on a number of features, such as the homology
to transcription factor binding sites, the coincidence with
splicing sites, or amino acid changes [14-16]. We chose
variations with a minor allelic frequency > 5% in Cauca-
sian populations and thus selected rs6260, rs6257, and
rs6259. We also included rs1799941 based on some liter-
ature reports suggesting an association with SHBG levels
[8]. Genomic DNA was obtained from the peripheral
blood using a commercial kit, according to the manufac-
turer's instructions (Qiagen, Hilden, Germany). SHBG
genotyping was performed by means of a procedure based
on the exonuclease activity of Taq DNA-polymerase, using
allele-specific Taqman probes labelled with VIC and FAM.
Primers and probes were designed by the manufacturer
with Primer Express software (Applied Biosystems, Foster
City, CA, USA). After amplification in an ABI9700 ther-
mal cycler (Applied Biosystems), the fluorescence was
read in an ABI7300 sequence detector. Random samples
were analysed twice to check for consistency of results.
Statistics
Hardy-Weinberg equilibrium (HWE) was checked with
HWSIM software (available at http://krunch.med.yale.ed
u/hwsim/). Linkage disequilibrium measures were esti-
mated with Haploview software [17]. SHBG values did
not follow a normal distribution, thus their natural loga-
rithms were computed prior to statistical analysis.
Between-genotype comparisons were done by means of
general linear models, with and without adjustment for
possible confounders, and by linear regression, assuming
an additive genetic model by coding genotypes numeri-
cally as 1,2 (heterozygotes) and 3, and using SPSS soft-
ware (SPSS Inc., Chicago, IL, USA). Power calculations
were done with Quanto software (Gauderman WJ, Morri-
son JM. QUANTO 1.2: A computer program for power
and sample size calculations for genetic-epidemiology
studies, http://hydra.usc.edu/gxe, 2006).
Results
The rs6260 locus had very little variation in our popula-
tion, with a minor allele frequency of 0.5% and was thus
not considered further in the analysis. The minor allelic
frequencies for rs6257 (C), rs6259 (A), and rs1799941
(A) were 16%, 15%, and 27%, respectively. There was no
evidence for deviation from the HWE. The three polymor-
phisms exhibited significant linkage disequilibrium
(rs1799941-rs6259: D' = 1.0, r2  = 0.05, p < 0.001;
rs1799941-rs6257: D' = 0.81, r2 = 0.03, p = 0.03; and
rs6257-rs6259: D' = 1.0, r2 = 0.01, p = 0.01).
Based on univariate regression analysis, age, body weight,
and the polymorphisms were significantly associated with
serum SHBG levels measured in 307 randomly selectedBMC Medical Genetics 2008, 9:112 http://www.biomedcentral.com/1471-2350/9/112
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women of the control and osteoporotic subgroups.
Among the polymorphisms, rs1799941 and rs6257
showed a stronger association with serum SHBG than
rs6259 (Table 1). When the results were adjusted by age
and weight, the associations of rs1799941 and rs6257
genotypes with serum SHBG remained statistically signif-
icant (p = 0.0004 and 0.009, respectively). In Figure 1, the
age and weight-adjusted SHBG levels across rs1799941
genotypes are shown. The SHBG levels in AA homozy-
gotes were 39% higher than in GG homozygotes. Based
on multiple linear regression models, age and weight
together accounted for 10.5% of the variance of serum
SHBG; the inclusion of the rs1799941 genotype explained
a further 3.7% of the SHBG variance. The inclusion of
other polymorphisms did not further increase the propor-
tion of variance explained.
Serum SHBG showed a negative association with BMD (p
= 0.040 at the spine and 0.014 at the hip). Thus, we next
determined the association between the rs1799941 allele
and BMD and osteoporotic fractures; however, there were
no genotype-related significant differences in the spine or
hip BMD (Table 2), nor in the distribution of genotypes
in women with and without fractures (Table 3). The study
had 87% power to detect an association between
rs1799941 polymorphisms and BMD if at least 2% of the
BMD variance was explained. Likewise, the power to
detect an association with vertebral and hip fractures was
87% and 96%, respectively, assuming a risk ratio of 1.6.
Discussion
The SHBG gene is located on chromosome 17 and the
major transcript is encoded by 8 exons, spanning approx-
imately 3.2 Kb. In the present study, we report that several
polymorphisms of the SHBG gene are strongly associated
with serum SHBG levels in postmenopausal women. In
particular, women with the AA genotype at the rs1799941
locus had 39% higher SHBG levels than those with the
GG genotype. This polymorphism is located in the 5'
region of the gene, 8 nucleotides upstream of the tran-
scription start site. Thus, it is well situated to influence
gene transcription. In fact, higher SHBG serum levels have
also been recently reported in men and women bearing A
alleles, in comparison with those with G alleles. Dunning
et al. [18] found that SHBG serum levels were 28% higher
in women with the AA genotype than in those with the
GG genotype. Similarly, Eriksson et al. [8] found 22% and
26% higher SHBG levels in individuals with the AA geno-
type in two cohorts of Swedish men. The C/T rs6257 pol-
ymorphism was also associated with SHBG levels in the
present study. The mechanism is unclear, as it is located in
an intronic region (intron 1). A search of potentially func-
tional polymorphisms with the PupaSuite web-based tool
revealed that it is located in a potential binding site for the
transcription factor hepatocyte nuclear factor 3/Fox. The
A/G rs6259 polymorphism is located in exon 8 and causes
a change in the amino acid sequence of SHBG (Asn>Asp).
It was also associated with SHBG levels, but to a lesser
extent than the other polymorphisms. It has been sug-
gested that the Asn>Asp modification affects a potential
glycosylation site and increases the half-life of the protein
coded for the less common allele [6]. Previous studies of
the relationship of this SNP with serum SHBG in women
have given conflicting results [6,9,18].
Our results show a clear association between several
SHBG gene polymorphisms and serum SHBG levels, but
since they are in linkage disequilibrium, we cannot estab-
lish with certainty which polymorphism is truly responsi-
ble for the association. On the other hand, we cannot
exclude the possibility that other polymorphisms in link-
age disequilibrium with those studied herein are actually
responsible for the association with SHBG levels [6,8].
Serum SHBG showed a stronger association with
rs1799941 than with other loci. However, allelic frequen-
cies of rs1799941 were more balanced than those of other
polymorphisms, which may favour the detection of asso-
ciations between genotypes and SHBG levels.
Several authors have reported an association between
serum SHBG and BMD or osteoporotic fractures [19-24].
In the present study, we did not find an association
between SHBG alleles and BMD, despite the fact that they
were strongly associated with serum SHBG levels, which
in turn was associated with BMD. This lack of association
between SHBG genotype and BMD may be due merely to
the multiple factors influencing these traits and introduc-
ing noise in the relationship between genotype, serum
SHBG levels, and BMD. Although the association between
genotypes and serum SHBG was statistically significant
and quantitatively important (39% difference between AA
and GG genotypes), there was wide inter-individual vari-
ation, and thus rs1799941 alleles explained < 4% of
serum SHBG variance. Similarly, the contribution of
serum SHBG to BMD variance was rather small (SHBG
explained 2% of the BMD variance at the spine and 3% at
the hip). Thus, given the moderate sample size of this
Table 1: Factors associated with serum SHBG levels (Beta 
standarized regression coefficients and p values from univariate 
and multivariate regression analyses)
Univariate Age- and weight-adjusted
Beta p Beta p
Age 0.17 0.002
Weight 0.28 0.00006
rs6257 0.15 0.010 0.14 0.009
rs1799941 0.14 0.0015 0.19 0.0004
rs6259 0.11 0.048 0.06 0.27BMC Medical Genetics 2008, 9:112 http://www.biomedcentral.com/1471-2350/9/112
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study, we cannot completely exclude a small effect of
SHBG polymorphisms on BMD or fractures, but our data
suggest that such effect, if any, is unlikely to be clinically
important in postmenopausal women.
It is also worth noting that SHBG may have a complex
influence on estrogen activity and, consequently in the
homeostasis of estrogen-responsive tissues, such as bone.
It is generally accepted that the unbound fraction of sex
steroids is the biologically important fraction because it
can diffuse from the capillaries into the peripheral tissues.
However, SHBG may be synthesized in certain target tis-
sues and some cells appear to have specific binding sites
for SHBG and actively internalize it, through the megalin
and other pathways [25-27]. Although the true biological
significance of this phenomenon is unclear, it might rep-
resent a mechanism increasing estrogen activity on the tar-
get tissues. The results of some studies appear to be in line
with this hypothesis. In fact, although a negative associa-
tion between SHBG and BMD or fractures was reported in
several studies [19-21] others found a direct positive cor-
relation between serum SHBG levels and hip BMD [8].
Thus, it has been suggested that increasing SHBG may
either facilitate or impair estradiol action on target tissues,
depending on several factors, including the overall estro-
gen status [25].
The results of genetic association studies may be biased by
a number of factors, including genotyping and phenotyp-
ing errors, and population stratification. Good clinical
and laboratory practices can diminish the impact of such
errors, but the confounding effect of population substruc-
ture may be particularly difficult to exclude [28]. Never-
theless, we tried to avoid it by studying women in a
relatively small region and excluding those with non-
Spanish ancestors. Given the moderate size of our study,
SHBG levels according to rs1799941 (mean and SEM of age- and weight-adjusted values) Figure 1
SHBG levels according to rs1799941 (mean and SEM of age- and weight-adjusted values).
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Table 2: Spine and hip BMD according to rs1799941 genotypes (mean (SE) and 95% confidence intervals after age- and weight-
adjustment)
Spine Hip
Genotype Mean (SE) 95% CI p Mean (SE) 95% CI p
AA 0.815 (0.027) 0.763–0.868 0.9 0.807 (0.021) 0.766–0.848 0.9
AG 0.820 (0.013) 0.794–0.845 0.799 (0.010) 0.779–0.819
GG 0.823 (0.010) 0.803–0.843 0.802 (0.008) 0.786–0.818BMC Medical Genetics 2008, 9:112 http://www.biomedcentral.com/1471-2350/9/112
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a relatively small, but still clinically significant effect (i.e.,
a 1.2 odds ratio for fracture) cannot be excluded. On the
other hand, we cannot exclude the possibility that other
polymorphisms in the SHBG gene region might have an
influence on BMD or fracture risk. The SHBG gene is small
and only a few SNPs are included in the Hapmap data-
base. Therefore, we focused on potentially functional
SNPs, rather than in haplotype-tagging SNPs.
Conclusion
Our results show that apart from other factors, such as age
and body weight, some common genetic variants of the
SHBG gene, and particularly an A/G polymorphism situ-
ated in the 5' region, influence serum SHBG, but we have
not been able to demonstrate its association with either
BMD or osteoporotic fractures.
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